GalantNews November 20 | Insigma Technology, a wholly-owned subsidiary of Insigma Technology, announced that its investee company Hangzhou Juyuan Genomics Engineering Co., Ltd. (referred to as Juyuan Genomics) disclosed its prospectus on the Hong Kong Stock Exchange website on November 20, 2024, planning to conduct a global offering. The public offering in Hong Kong includes 4,540,000 H shares (available for redistribution), and the international offering includes 40,858,800 H shares (available for redistribution and subject to adjustment based on the exercise of the over-allotment option), with a price range of HK$11.48-12.56. H&D Capital (Hong Kong) Limited, Fosun Industrial (Hong Kong) Limited, Hong Kong Healthmate Industries Limited, Ali Health (Hong Kong) Technology Limited, Jointown International Group Company Limited, Delta Capital Hong Kong Limited, and Wu Qiyuan act as cornerstone investors, intending to subscribe to a total amount of approximately 0.35 billion Hong Kong dollars of shares at the offering price. According to the prospectus, Juyuan Genomics began its public offering in Hong Kong on November 20, with Juyuan Genomics H shares expected to start trading on the Hong Kong Stock Exchange main board on November 28, 2024, under the stock code 2566.